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The 14-3-3 proteins positively regulate rapamycin-sensitive
signaling
Paula G. Bertram, Chenbo Zeng, John Thorson, Andrey S. Shaw 
and X.F. Steven Zheng
Background: The kinase Tor is the target of the immunosuppressive drug
rapamycin and is a member of the phosphatidylinositol kinase (PIK)-related
kinase family. It plays an essential role in progression through the G1 phase of
the cell cycle. The molecular details of Tor signaling remain obscure, however.
Results: We isolated two Saccharomyces cerevisiae genes, BMH1 and BMH2,
as multicopy suppressors of the growth-inhibitory phenotype caused by
rapamycin in budding yeast. BMH1 and BMH2 encode homologs of the 14-3-3
signal transduction proteins. Deletion of one or both BMH genes caused
hypersensitivity to rapamycin in a manner that was dependent on gene dosage. In
addition, alterations in the phosphopeptide-binding pocket of the 14-3-3 proteins
had dramatically different effects on their ability to relieve the growth-arresting
rapamycin phenotype. Mutations that prevented 14-3-3 from binding to a
phosphoserine motif abolished its ability to confer rapamycin resistance. In
contrast, substitution of two residues in 14-3-3 that surround these
phosphoserine-binding sites conferred a dominant rapamycin-resistant phenotype. 
Conclusions: Our studies reveal 14-3-3 as an important component in
rapamycin-sensitive signaling and provide significant new insights into the
structure and function of 14-3-3 proteins.
Introduction
The 14-3-3 proteins are a family of highly conserved and
abundant proteins found throughout the eukaryotic
kingdom. They exist as multiple isoforms and have been
implicated as key regulators of diverse intracellular signal
transduction processes [1]. The 14-3-3 proteins bind to
two different types of 14-3-3-binding motifs, RSXpSXP
and RXY/FXpSP (in single-letter amino-acid code where
X is any amino acid and pS is a phosphoserine residue)
[2–4]. Direct interaction of 14-3-3 with a number of other
signaling proteins via these phosphopeptide motifs has
been demonstrated recently and shown to be critical for
the signaling functions in which 14-3-3 is implicated.
There are two Saccharomyces cerevisiae 14-3-3 homologs,
Bmh1p and Bmh2p, which share redundant functions for
cell viability in most budding yeast strains. Their essential
function can be complemented by several plant 14-3-3 iso-
forms [5,6]. Bmh1p and Bmh2p appear to be involved in
signaling from the GTPase Ras via protein kinase A, in
vesicular transport [7] and in the Ras–mitogen-activated
protein (MAP) kinase cascade that functions during
pseudohyphal development [8]. In the Σ1278b genetic
background, yeast lacking both BMH1 and BMH2 are
viable, but have many abnormalities such as temperature-
sensitive growth, accumulation of glycogen and hypersen-
sitivity to environmental stresses [8]. In Schizosaccharomyces
pombe there are two 14-3-3 homologs, Rad24 and Rad25,
which were identified as DNA-damage checkpoint pro-
teins [9] and proposed to be essential in a checkpoint
involving Chk1 and the phosphatidylinositol kinase (PIK)-
related kinase Rad3 [10].
Rapamycin is a potent immunosuppressant antibiotic.
When complexed with its immunophilin receptor FK506-
binding protein 12 (FKBP12), rapamycin inhibits progres-
sion through the G1 phase of the cell cycle in mammalian
cells and yeast. The yeast ‘target of rapamycin’ proteins
Tor1p and Tor2p and their mammalian homolog the
FKBP–rapamycin-associated protein FRAP (also called
RAFT or mTOR) were identified recently [11,12] and are
members of the PIK-related kinase family. Despite their
sequence similarities to phosphatidylinositol kinases, PIK-
related kinases are thought to function as protein kinases
[13,14]. FRAP was recently shown to have a Ser/Thr
protein kinase activity in vitro. It can autophosphorylate
and can phosphorylate the translation inhibitor eIF4e-
binding protein 1 (4EBP1/Phas-1) [15–18] and p70 S6
kinase [18]. The FKBP12–rapamycin complex binds to
the FKBP–rapamycin-binding (FRB) domain of Tor pro-
teins [19,20] and inhibits the protein kinase activity of
Tor1p (C.Z. and X.F.S.Z., unpublished observations).
Treating yeast with rapamycin or deleting both TOR1 and
TOR2 causes the cells to growth arrest as well as causing
several physiological changes characteristic of starvation,
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including an increase in intracellular glycogen storage and
severely reduced protein synthesis [21]. In this study, we
show for the first time that 14-3-3 positively regulates
rapamycin-sensitive signal transduction.
Results
BMH1 and BMH2 as multicopy suppressors of the growth-
inhibitory phenotype caused by rapamycin
To identify components of the rapamycin-sensitive Tor
signaling pathway, we screened for multicopy suppressors
of the growth-inhibitory phenotype caused by rapamycin.
A YEp13-based 2µ (multicopy) yeast genomic DNA
library was introduced into yeast strain EGY48 and
selected on medium lacking leucine (SC Leu–) and con-
taining rapamycin; 26 clones were isolated that showed
plasmid-dependent suppression of the growth-inhibitory
phenotype conferred by rapamycin. All the genomic
inserts fell into two related groups (Figure 1a). A common
feature of the first group was that all the clones contained
the BMH1 open-reading frame (ORF), whereas the inserts
in the second group contained an intact BMH2 ORF. The
majority of the genomic DNA inserts had different break-
points, suggesting that they were independent clones.
BMH1 and BMH2 are related to each other and are the
two S. cerevisiae homologs of the 14-3-3 family. Partial or
complete deletion of BMH1 or BMH2 resulted in com-
plete loss of their ability to confer rapamycin resistance
(Figure 1a), indicating that BMH1 and BMH2 are the
responsible suppressors. We further found that overex-
pression of either the BMH1 or BMH2 ORF alone was suf-
ficient to confer rapamycin resistance in yeast (Figure 1b).
Together, these experiments indicate that BMH1 and
BMH2, when overexpressed, can suppress the growth-
inhibitory phenotype caused by rapamycin.
Lack of one or both BMH genes causes hypersensitivity to
rapamycin in yeast
We next tested the rapamycin sensitivity of yeast when
the endogenous Bmh1p and Bmh2p are absent as a result
of gene disruption. Yeast strains derived from the Σ1278b
genetic background were chosen here because loss of both
BMH1 and BMH2 alleles does not result in lethality [8]. In
low concentrations of rapamycin, wild-type yeast cells
were still viable, but grew at a much slower rate. Haploid
strains lacking either the BMH1 or the BMH2 allele grew
significantly more slowly than the wild-type strains
(Figure 1c). We noted consistently that the bmh1 BMH2
strain grew slightly more slowly than the BMH1 bmh2
strain when treated with rapamycin (Figure 1c). This dif-
ference became more apparent in diploid strains (data not
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Changes in the expression levels of Bmh1p and Bmh2p alter yeast
sensitivity to rapamycin. (a) Identification of BMH1 and BMH2 as
multicopy suppressors of the growth-inhibitory phenotype caused by
rapamycin. Rapamycin-resistance clones (RR) identified in this study
fell into two distinct groups represented by RR17 and RR6,
respectively. The arrows show the arrangement of the ORFs and
restriction enzyme sites are indicated. RR6 and RR17 were subjected
to deletional analysis; the deletion clones were assayed for their
rapamycin-resistant phenotype (RapR) by incubation on SC Leu–
medium with rapamycin at 30°C. Rapamycin-resistant clones are
labeled +; rapamycin-sensitive clones, –. (b) Overexpression of BMH1
or BMH2 alone conferred rapamycin resistance. EGY48 yeast strains
carrying a vector control (pBF339), or carrying plasmids expressing
the rapamycin-resistant mutant Tor1S1972I (TORSI) or hemagglutinin
(HA)-tagged Bmh1p (ADH1 promoter, 2µ) or HA–Bmh2p (ADH1,
2µ), were streaked onto SC Trp– plates with or without rapamycin and
incubated at 30°C. (c) Disruption of BMH1 and/or BMH2 causes
hypersensitivity to rapamycin. Wild-type and bmh haploid strains were
streaked onto YPD plates with or without rapamycin and incubated for
2 days without rapamycin, or for 5 and 10 days with 100 nM
rapamycin, at 30°C.
shown). Disruption of both BMH1 and BMH2 alleles
resulted in dramatic hypersensitivity to rapamycin
(Figure 1c). In fact, both the haploid bmh1 bmh2 and the
diploid bmh1 bmh1/bmh2 bmh2 strains showed no signs of
growth even when incubated for 10 days. In addition,
expression of BMH1 or BMH2 on a centromere plasmid
reduced rapamycin sensitivity of bmh1 bmh2 strains (data
not shown).
Bmh1p and Bmh2p are not involved in general drug
resistance in yeast
One possible explanation for the effects of Bmh1p and
Bmh2p is that they are involved in general drug resis-
tance. Eukaryotic cells have developed sophisticated
mechanisms of detoxification. For example, overexpres-
sion of multi-drug resistant (MDR) genes can lead to a
dramatic reduction in the sensitivity of yeast to a variety of
drugs [22]. To explore this possibility, we examined the
effects of overexpressing BMH1 and BMH2 on the sensi-
tivity of yeast to cycloheximide. Like rapamycin, cyclo-
heximide is a potent protein synthesis inhibitor of
Streptomyces origin. In contrast to rapamycin, however,
overexpression of BMH1 or BMH2 had no detectable
effect on cycloheximide sensitivity (Figure 2a).
We also tested whether Bmh1p and Bmh2p might be
involved in drug resistance to the family of structurally
related immunosuppressive antibiotics that bind to
FKBP12, which includes rapamycin and FK506. Bmh1p
and Bmh2p might confer resistance to this drug family via
a general drug-resistant mechanism or by interfering with
the binding of the drugs to FKBP12. Although both
FK506 and rapamycin bind to the same active site of
FKBP12, FKBP12–rapamycin inhibits the Tor family
kinases, whereas FKBP12–FK506 inhibits calcineurin, a
protein phosphatase necessary for Ca2+-dependent cell
signaling. In yeast, calcineurin is required for resistance to
high salt stress conditions; it promotes export of excessive
Na+ and Li+ ions. Inhibition of calcineurin by
FKBP12–FK506 impairs the ability of yeast to resist high
concentrations of LiCl [23,24]. We found that overexpres-
sion of BMH1 or BMH2 did not have any appreciable
effect on yeast sensitivity to FK506 in 0.16 M LiCl
(Figure 2b). Calcineurin is also required in yeast for the
expression of the PMC1 gene that is involved in tolerance
to high Ca2+ [25]. PMC–lacZ reporter constructs have been
established to measure calcineurin activity in vivo [26,27].
We found that overexpression of BMH1 or BMH2 did not
cause any detectable reduction in the FK506-sensitive
lacZ expression (Figure 2c). These results indicate that
Bmh1p and Bmh2p do not confer resistance to the
FKBP12-binding antibiotics. 
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Figure 2
Bmh1p and Bmh2p are not involved in general drug resistance.
(a) Overexpression of BMH1 and BMH2 did not cause cycloheximide
(CHX) resistance. A cycloheximide-resistant strain Y190 (CHXR)
carrying a vector control (pBF339), and cycloheximide-sensitive Y187
strains (CHXS) carrying a vector control (pBF339) or carrying
plasmids expressing the rapamycin-resistant mutant Tor1pS1972I
(TOR1SI), HA–Bmh1p (ADH1, 2µ) or HA–Bmh2p (ADH1, 2µ), were
streaked onto SC Trp– plates with or without cycloheximide (10 µg/ml)
and incubated at 30°C. Overexpression of BMH1 or BMH2 conferred
rapamycin resistance in Y190 and Y187 under similar conditions (data
not shown). (b) Overexpression of BMH1 and BMH2 did not confer
resistance to FK506 and LiCl. EGY48 strains carrying a vector control
(pBF339), or plasmids expressing the rapamycin-resistant Tor1pS1972I,
HA–Bmh1p (ADH1, 2µ), or HA–Bmh2p (ADH1, 2µ) were incubated
on a SC Trp– plate until colonies appeared. Replicas were made onto
YPD, YPD with 0.16 M LiCl, or YPD with 0.16 M LiCl and 1 µM
FK506, and incubated at 30°C (we found that SC Trp– plates with
LiCl were too soft for these experiments). In a similar replica
experiment, HA–Bmh1p (ADH1, 2µ) and HA–Bmh2p (ADH1, 2µ)
conferred rapamycin resistance when plated on YPD with rapamycin
(data not shown). (c) Overexpression of BMH1 and BMH2 did not
cause a reduction in FK506-sensitive Ca2+-inducible transcription.
EGY48 strains carrying pKC190 and a vector control (pBF339), or a
plasmid expressing HA–Bmh1p (ADH1, 2µ) or HA–Bmh2p (ADH1,
2µ) were cultured in SC Leu– Trp– at 30°C in the presence or
absence of 200 nM FK506 and 100 mM CaCl2. The Ca2+-responsive
lacZ expression levels shown are the mean results from three
independent experiments.
Vector
BMH2 TOR1SI
Normal + Li+  Li+ + FK506
Vector
CHXR
BMH2 Vector
CHXS
TOR1SI
– CHX + CHX(a)
(b)
BMH1
BMH1
(c)
0
20
40
60
80
100
120

la
cZ
 e
xp
re
ss
io
n 
(%
)
FK506 + + – – + + – – + + – –
CaCl2 – + – + – + – + – + – +
Control BMH1 BMH2
Current Biology   
Bmh1p and Bmh2p do not directly relieve Tor1p from
inhibition by FKBP12–rapamycin
We have recently shown that Tor1 has an intrinsic Ser/Thr
protein kinase activity that uses mammalian 4EBP-1 as an
artificial substrate (C.Z. and X.F.S.Z., unpublished obser-
vations). FKBP12–rapamycin potently inhibits Tor1p
kinase activity both in vivo and in vitro. Bmh1p and
Bmh2p could antagonize rapamycin inhibition by activat-
ing Tor1p kinase activity or by directly preventing binding
of FKBP12–rapamycin to Tor1p or Tor2p. We found that
overexpression of BMH1 failed to relieve Tor1p from inhi-
bition by FKBP12–rapamycin at any detectable level in
vivo. In contrast, Tor1pS1972I, a rapamycin-resistant mutant
of Tor1p that does not interact with FKBP12–rapamycin,
showed significant rapamycin-resistant kinase activity
(Figure 3a). In addition, incubation of cell-free yeast
extracts with bacterially expressed recombinant glu-
tathione-S-transferase (GST)–Bmh1p or GST–Bmh2p
before the extracts were treated with rapamycin did not
affect the inhibition of Tor1p protein kinase activity by
rapamycin (Figure 3b,c). These observations suggest that
Bmh1p and Bmh2p do not directly antagonize the inhibi-
tion of Tor1p and Tor2p by FKBP12–rapamycin. In addi-
tion, we have not been able to obtain any evidence that
Tor1p directly interacts with Bmh1p or Bmh2p (data not
shown), which is consistent with the lack of consensus 14-
3-3-binding sites in either Tor1p or Tor2p. Thus, Bmh1p
and Bmh2p are unlikely to act directly on Tor1p or Tor2p
to relieve rapamycin inhibition. 
Mammalian 14-3-3 genes can also confer a rapamycin-
resistant phenotype in yeast
The 14-3-3 proteins exist in multiple isoforms and are
conserved across species. The yeast and higher eukaryotic
14-3-3 proteins have highly conserved phosphoserine-
ligand-binding pockets. Several plant 14-3-3 isoforms have
been shown to complement the essential functions of
BMH1 and BMH2 in certain yeast strains [5,6]. Con-
versely, Bmh1p and Bmh2p can regulate human c-Raf-1
activity in yeast [28]. We asked whether the rapamycin-
suppressing activity of 14-3-3 proteins is isoform-depen-
dent or species-dependent. Three human 14-3-3 isoforms
(β, τ and η), when overexpressed, were sufficient to confer
rapamycin resistance at a comparable level to Bmh1p and
Bmh2p (Figure 4). Thus, the rapamycin-sensitive function
of 14-3-3 proteins is conserved across species and appears
to be isoform-independent. These results also suggest that
14-3-3 proteins have similar roles in Tor signaling in
higher eukaryotes.
The phosphoserine-ligand-binding pocket is crucial for
14-3-3 function in rapamycin-sensitive signaling
Direct binding to conserved phosphoserine motifs is critical
for the functions of 14-3-3 proteins in regulating diverse
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Figure 3
Bmh1p and Bmh2p fail to relieve Tor1p from inhibition by
FKBP12–rapamycin. (a) EGY48 strains containing a vector control,
overexpressing Bmh1 (2µ), or expressing HA–Tor1pS1972I as a positive
control, were incubated in SC Leu– Trp– with or without different
concentrations of rapamycin for 1 h. HA–Tor1p was
immunoprecipitated and its protein kinase activity assayed. A typical
result from several experiments is shown. (b) A cell-free extract
prepared from EGY48 expressing HA–Tor1p was incubated first with
Bmh1p at different concentrations for 30 min then with 25 nM
rapamycin for another 30 min. HA–Tor1p was immunoprecipitated with
monoclonal antibody 12CA5 and assayed for its protein kinase activity
towards 4EBP1. (c) The same as (a) except that the cell lysates were
preincubated with 0.5 µM of each of GST, Bmh1p or Bmh2p.
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Figure 4
Overexpression of three mammalian 14-3-3 isoforms confers a
rapamycin-resistant phenotype in yeast. EGY48 strains carrying a
control vector (BF339), or overexpressing 14-3-3β, η or τ were streaked
onto SC Trp– plates with or without rapamycin and incubated at 30°C.
Vector
β
ητ
+ Rapamycin
Current Biology   
– Rapamycin
signaling proteins [2,3]. The 14-3-3 protein forms a large,
negatively charged pocket, the interior of which contains
amino acids that are almost invariant throughout the family.
The three-dimensional 14-3-3ζ–phosphopeptide structure
provides details of the interaction between this conserved
pocket and a phosphoserine ligand [3]. The phosphate is
held by an array of interactions involving the side chains of
amino-acid residues K49 and R56 from helix C and Y128
and R127 from helix E. Mutations in the ligand-binding
pocket of 14-3-3η showed dramatically different affinities
for RSApSEP, a phosphopeptide ligand derived from Raf-1
[29]. The 14-3-3 mutants were overexpressed in yeast and
assayed for their ability to confer a rapamycin-resistant phe-
notype; their behavior is summarized in Table 1. Mutations
R56A/R60A and R132K abolished the ability of 14-3-3 to
bind the phosphoserine peptide. These mutant 14-3-3 pro-
teins also failed to confer the rapamycin-resistant pheno-
type (Figure 5a). In contrast, three other mutations, V51A,
R55A and Y216F, did not affect phosphopeptide binding
and these mutant 14-3-3 proteins conferred the rapamycin-
resistant phenotype. A third type of mutation we examined
was E185K. This mutation was originally identified as a
suppressor of the activated RAS allele during Drosophila
eye development [30]. E185 corresponds to E183 in 14-3-
3ζ. Although the E185K 14-3-3 mutant was only slightly
defective in binding to the Raf-1 phosphopeptide, it was
completely inactive in conferring rapamycin resistance
(Table 1, Figure 5a). Further investigation is needed to
understand the nature of the effect of this mutant. The dif-
ferent 14-3-3η mutants were expressed in yeast at a similar
level, suggesting that the differences in their activities in
vivo were not due to differences in their stability or expres-
sion level (Figure 5b). 
Three BMH1 mutations, L232S (bmh1-1), G55D (bmh1-2)
and A59T (bmh1-3), were recently described as partial
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Table 1
Mutations in the ligand-binding pocket affect the ability of 14-3-3h to confer a dominant rapamycin-resistant phenotype.
14-3-3η C WT R56A/R60A V51A R55A R132K E185K Y216F
Binding to n/a ++++ +/– ++++ ++++ – +++ +++
phosphopeptide
Rapamycin-resistant – ++++ +/– ++++ ++++ – – +++
phenotype
A summary of the abilities of wild-type (WT) and mutant 14-3-3η
proteins to bind to a phosphopeptide (RSApSEP) derived from Raf-1
as described by Thorson et al. [29], and to confer rapamycin
resistance (Figure 5a). The relative activities of different 14-3-3η
proteins to bind to RSApSEP and to confer rapamycin resistance are
indicated by the number of + symbols. C indicates control vector; n/a,
not applicable. 
Figure 5
Different mutations affect the ability of 
14-3-3η to confer a rapamycin-resistant
phenotype. (a) EGY48 strains carrying a
vector control (C; pAUD6-2) or carrying
plasmids overexpressing wild-type (WT) or
mutant 14-3-3η proteins (ADH1, 2µ) as
indicated were streaked onto SC Ura– plates
with or without rapamycin and incubated at
30°C. (b) Western blotting analysis of the
wild-type and mutant Myc-epitope-tagged 
14-3-3η proteins from the yeast used in (a).
Myc–14-3-3η
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loss-of-function mutations that completely abolish the
activity of the MAP kinase signaling cascade that functions
during pseudohyphal development [8]. The same muta-
tions do not appear to affect other functions of Bmh1p,
however [8]. These mutated residues correspond to L230,
G53 and A57, respectively, in 14-3-3ζ, based on sequence
alignment. As these mutations lie in the ligand-binding
pocket, we also examined their effects on rapamycin-sensi-
tive signaling. To our surprise, a single copy of BMH1L232S
or BMH1G55D (on ARS/CEN plasmids) conferred strong
rapamycin resistance (Figure 6). In contrast, a single copy
of wild-type BMH1 (Figure 6) or BMH1A59T (data not
shown) did not confer rapamycin resistance. All three
BMH1 mutants and the wild-type BMH1 were carried on
the same centromere plasmid vector and were expressed at
similar levels under the control of the BMH1 promoter [8]
(see Supplementary material published with this paper on
the internet). Thus, L232S and G55D appear to be gain-
of-function mutations that enhance the activity of 14-3-3
in rapamycin-sensitive signaling.
Discussion
In this study we have isolated BMH1 and BMH2, two
yeast 14-3-3 homologs, as multicopy suppressors of the
growth-inhibitory phenotype caused by rapamycin. Inter-
estingly, BMH1 and BMH2 were repeatedly isolated and
were the only strong suppressors of the rapamycin pheno-
type, suggesting that they play a critical role in rapamycin-
sensitive signaling. Loss of BMH1 and BMH2 individually
or in combination led to hypersensitivity to rapamycin.
Overexpressing BMH1 or BMH2 did not cause decreased
sensitivity of yeast to antibiotics in general or to antibiotics
related to FK506 that bind to FKBP12. Bmh1p and
Bmh2p did not appear to directly interact with Tor family
proteins or to relieve rapamycin inhibition in vivo or in
vitro. In addition, the L232S and G55D mutations in
BMH1 were sufficient to confer dominant rapamycin resis-
tance. These results demonstrate that 14-3-3 is a key com-
ponent in rapamycin-sensitive signaling.
The 14-3-3 proteins constitute a highly conserved family
with multiple isoforms [1]. Our results show that Bmh1p
and Bmh2p are redundant in rapamycin-sensitive signal-
ing, and that at least three mammalian isoforms (β, τ and
ζ) can complement such a function. Thus, different 
14-3-3 proteins share a common function in conferring
rapamycin resistance. Given that the rapamycin-sensitive
pathway is well conserved, Tor from higher eukaryotes
may also use 14-3-3 in its signal transduction pathway.
Substitution of invariant residues in the conserved ligand-
binding pocket of 14-3-3 showed dramatically different
effects on the ability of 14-3-3 to bind to a Raf-1 phospho-
serine peptide. Residues R56, R60 and R132 directly
interact with the phosphate of the Raf-1 peptide [3].
Mutations R56A/R60A or R132K abolished the ability of
14-3-3 to bind to the Raf-1 peptide. When overexpressed,
these mutant proteins also failed to confer a rapamycin-
resistant phenotype. In contrast, residues V51, R55 and
Y216 are not directly involved in substrate interaction.
They do not individually affect substrate binding or the
ability of 14-3-3 to confer a rapamycin-resistant pheno-
type. These results demonstrate that binding to a phos-
phoserine motif(s) is critical for 14-3-3 to mediate Tor
signaling. One particularly interesting mutation is E185K,
which was originally isolated from Drosophila as a domi-
nant-negative mutation in Ras–Raf signaling during eye
development [30]. Although the E185K mutant could
bind to the Raf-1 peptide at near wild-type affinity, it
failed to confer a rapamycin-resistant phenotype. In con-
trast, Y216F, another mutation isolated in the same
screen, did not affect the ability of 14-3-3 to confer
rapamycin resistance. One interpretation for these con-
flicting observations is that 14-3-3 recognizes a slightly
different phosphoserine motif in the two distinct path-
ways. In a mammalian transfection experiment, Y216F
behaved as a dominant-negative in Ras–Raf-1 signaling,
whereas E185K did not [29].
We have identified two dominant gain-of-function muta-
tions, L232S and G55D, in Bmh1p. Either mutant can
confer a rapamycin-resistant phenotype when expressed
as a single copy gene. The effects of these mutations are
highly selective. In fact, both mutations were originally
isolated as loss-of-function mutations in Ras–MAP kinase
signal transduction during pseudohyphal development [8].
How is it possible that these mutations cause dominant
gain-of-function in one pathway but loss-of-function in
another? Both L232 and G55 are localized in the con-
served ligand-binding pocket. One mechanistic model is
shown in Figure 7. In this model, residue S232 creates a
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Figure 6
Dominant gain-of-function mutations in BMH1
confer a strong rapamycin-resistant
phenotype. EGY48 strains overexpressing
Bmh1p (from a 2µ plasmid), or expressing
Bmh1p, Bmh1pL232S or Bmh1pG55D at low
levels (from an ARS/CEN plasmid) were
streaked onto SC Leu– plates with or without
rapamycin and incubated at 30°C.
BMH1
(2µ)
BMH1
(ARS/CEN)
L232S
(ARS/CEN)
G55D
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– Rapamycin + Rapamycin
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new hydrogen bond with a residue (for example N or Q)
that is adjacent to the phosphoserine in the ligand and in
close proximity to S232 in the three-dimensional structure
of the complex. This new hydrogen bond helps to stabi-
lize the 14-3-3–ligand interaction and enhances Tor sig-
naling. In contrast, it might not affect or might even
weaken the interaction with another phosphopeptide with
a different residue in the same position (for example the
Raf-1 ligand). Given that different 14-3-3 ligands have
slightly different sequences, pathway-specific mutant
alleles can be useful in dissecting the roles of 14-3-3 in
diverse signaling pathways.
How do 14-3-3 proteins participate in the rapamycin-sen-
sitive signaling pathway? They might directly interact
with a substrate of Tor1p or Tor2p, or they might bind to
a phosphoprotein that is a substrate of another protein
kinase further downstream. Phosphorylation of this effec-
tor of Tor1p or Tor2p is important for successful Tor sig-
naling. Binding of 14-3-3 to the phosphorylation site has
been shown to be important for protection of the labile
phosphate of the ligand, which maintains the ligand in
the correct active state [31,32]. As FKBP12–rapamycin
only partially inhibits Tor1p protein kinase activity with
maximal inhibition at 70%, one could imagine that over-
expression of 14-3-3 might further stabilize the 14-3-
3–ligand complex and lead to accumulation of the
phosphorylated effector to a normal physiological concen-
tration. Thus, enough signal could be generated even in
the presence of rapamycin to confer rapamycin-resistant
growth (Figure 7). Altogether, our study has defined a
new role for 14-3-3 in the context of Tor signaling and
provided new insights into the structure and function of
14-3-3 proteins. 
Materials and methods
Yeast strains, library screen and plasmids
Yeast strains are listed in Table 2. Standard yeast culture medium was
prepared. Various drugs were added as indicated to test yeast sensitiv-
ity. A YEp13-based yeast genomic library DNA (from K. Nasmyth) was
transformed into EGY48 and plated on SC Leu– plates containing
0.1 µg/ml rapamycin, and incubated at 30°C for 4 days. Large colonies
were picked for further analysis. To construct plasmids pBF-BMH1 and
pBF-BMH2, DNA fragments flanking the BMH1 and BMH2 ORFs were
amplified from RR17 and RR6, respectively, using PCR. BMH1 was
amplified using oligonucleotides 5′-CGGGATCCTGTCAACCA-
GTCGTGAAGA-3′ and 5′-CGGGATCCTTACTTTGGTGCTTCAC-
CTT-3′, and BMH2 was amplified using
5′-CGGGATCCTGTCCCAAACTCGTGAAGA-3′ and 5′-CGGGATC-
CTTATTTGGTTGGTTCACCTT-3′. PCR products were cloned sepa-
rately into pBF339. In pBF339, BMH1 and BMH2 are under the control
of the ADH1 promoter and were fused with an in-frame HA epitope.
DNA sequencing was carried out to confirm that no mutations were
generated in the PCR-amplified BMH1 and BMH2. To construct plas-
mids pGEX-BMH1 and pGEX-BMH2, BMH1 and BMH2 were excised
with BamH1, and cloned into the BamH1 sites of pGEX-3X (Pharma-
cia). For the pAUD6-human 14-3-3 expression plasmids, human 14-3-
3β, η and τ were excised from their pGEX-KT vector with BamH1 and
EcoRI and cloned into pAUD6 [33]. These genes are under the control
of the ADH1 promoter and are tagged with a c-Myc epitope at their
amino termini. To construct the 14-3-3η mutants in pAUD6, V51A,
R55A, R56A/R60A, R132K, E185K and Y216F were excised from their
pGEX-KT vectors with BamH1 and EcoR1 and cloned into pAUD6. The
plasmids carrying bmh1-1 (L232S), bmh1-2 (G55D) and bmh1-3
(A59T) mutants were generous gifts from G. Fink. PKC190 was a gen-
erous gift from K. Cunningham. BF339 (HA epitope, ADH1, 2µ, Trp1)
was a generous gift from Frank Li. Plasmids expressing HA–Tor1p and
HA–Tor1p (S1972I) were previously described [20].
GST fusion proteins, western blot analysis, and
β-galactosidase and protein kinase assays
GST–Bmh1p, GST–Bmh2p, GST–FKBP12 and GST–4EBP1 were pro-
duced in Escherichia coli BL21(DE3) and purified according to the man-
ufacturer’s protocol (Pharmacia). Yeast cells were lysed with glass beads
in disruption buffer (DB; 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM
EDTA, 1% NP-40 plus protease inhibitors, 1 mM PMSF and 5µg/ml 
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Figure 7
A model for the role of 14-3-3 in rapamycin-
sensitive signaling. TEF is an effector (or
ligand) in the rapamycin-sensitive signaling
pathway and is shown with or without a
phosphate group (P) on the serine (S) of the
14-3-3 binding motif. The dashed line on the
lower right-hand TEF protein indicates a
potential new hydrogen bond between S232
of Bmh1p (14-3-3) and an asparagine residue
(N) adjacent to the phosphoserine of the
ligand molecule. PPase indicates a protein
phosphatase that removes the phosphate
from TEF, and rap indicates rapamycin. The
number of TEF molecules (small or normal
numbers) in the cell are indicated. See text for
further details.
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leupeptin). A total of 200 µg protein was used for western blot analysis
with anti-HA (12CA10) and anti-Myc (9EC10) monoclonal antibodies. A
lacZ reporter plasmid (pKC190) was used to measure yeast sensitivity to
FK506. The culture conditions and β-galactosidase activity assays were
carried out as described [26]. Yeast expressing HA–Tor1p [20] were
grown to OD600 = 1 and were lysed as described above. For immunopre-
cipitation, 5 µg 12CA5 monoclonal antibodies were incubated with cell
lysates for 1 h at 4°C. The immunocomplexes were then captured by
protein-A–Sepharose beads (Pharmacia), washed three times with DB
and once with kinase buffer (KB; 20 mM Hepes, 10 mM MnCl2, pH 7.5),
and incubated with KB containing 1 µg 4EBP1 and 20 µM [γ-32P]ATP for
30 min at 30°C. The phosphorylated 4EBP1 was separated on an
SDS–polyacrylamide gel and analysed with a BioRad phosphoimager.
Supplementary material
A figure showing the expression levels of wild-type and mutant Bmh1p
is published with this article on the internet.
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S1Supplementary material
Figure S1
Expression of wild-type and mutant Bmh1p and Bmh2p. Levels of
Bmh1p and Bmh2p proteins were analyzed by western blotting with an
affinity-purified anti-human 14-3-3η polyclonal antibody [29]. Lane 1,
yeast strain BMH1 BMH2; lane 2, bmh1 bmh2; and lane 3,
bmh1 BMH2. Lanes 4–7, bmh1 bmh2 strains transformed with the
following centromere plasmids: control vector, BMH1, bmh1L232S
and bmh1G55D.
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